Seom guidelines for the treatment of gastric cancer 2015
Clin. transl. oncol. (Print)
; 17(12): 996-1004, dic. 2015. tab
Article
in English
| IBECS
| ID: ibc-147438
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced resectable tumor increase overall survival and should be considered standard treatments. In stage IV tumors, platinum-fluoropyrimidine-based schedule, with trastuzumab in HER2-overexpressed tumors, is the firstline treatment. Different therapies in second line have demonstrated in randomized studies their clear benefit in survival improvement (AU)
RESUMEN
No disponible
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Spain
/
Stomach Neoplasms
/
Barrett Esophagus
/
Adenocarcinoma
/
Helicobacter pylori
/
Lymph Nodes
/
Obesity
Type of study:
Controlled clinical trial
/
Diagnostic study
/
Practice guideline
/
Prognostic study
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2015
Document type:
Article
Institution/Affiliation country:
Consorcio Sanitario Parc Taulí/Spain
/
Hospital Universitari Germans Trias I Pujol de Badalona/Spain
/
Hospital Universitario 12 de Octubre/Spain
/
Hospital Universitario Central de Asturias (HUCA)/Spain
/
Hospital Universitario La Paz/Spain
/
Hospital Universitario Marqués de Valdecilla/Spain
/
Hospital Universitario Ramón y Cajal/Spain
/
Hospital Universitario de Burgos/Spain
/
Hospital de la Santa Creu i Sant Pau/Spain
